G1 Therapeutics (GTHX) Investor Presentation - Slideshow

Trilaciclib: Myelopreservation Therapy - Trilaciclib is a first-in-class myelopreservation therapy designed to protect bone marrow and immune system function from damage caused by chemotherapy[4, 14, 37] - The company is preparing for Trilaciclib launch in Q1 2021, co-promoting with Boehringer Ingelheim[5] - In a Phase 2 trial for metastatic triple-negative breast cancer (mTNBC), trilaciclib showed a statistically significant improvement in overall survival (OS) with a hazard ratio (HR) of 0.36 (p-value = 0.0015) compared to the control group[28] - In SCLC trials, patients receiving trilaciclib experienced a significant reduction in the mean duration of severe neutropenia in cycle 1, from 4 days (placebo + chemo) to 0 days (trilaciclib + chemo) [22] - In SCLC trials, the occurrence of severe neutropenia was reduced from 52.9% (placebo + chemo) to 11.4% (trilaciclib + chemo)[22] - In SCLC trials, the occurrence of G-CSF administration was reduced from 56.3% (placebo + chemo) to 28.5% (trilaciclib + chemo)[22] - In SCLC trials, the occurrence of RBC transfusions on/after 5 weeks was reduced from 26.1% (placebo + chemo) to 14.6% (trilaciclib + chemo)[22] - In SCLC trials, the occurrence of Grade 3/4 thrombocytopenia was reduced from 36.1% (placebo + chemo) to 19.5% (trilaciclib + chemo)[22] Rintodestrant: Oral SERD - Rintodestrant is a potential best-in-class oral SERD (selective estrogen receptor degrader) for ER+ breast cancer treatment[4, 37] - Phase 1 data showed ER occupancy ≥ 80% in doses ≥ 600 mg, with preliminary evidence of anti-tumor activity[41]